- Trials with a EudraCT protocol (216)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
		
	   		
	   		    
                    
                   	
                   	    216 result(s) found for: Metabolic bone disease.
                    
                
			
   			
		
		Displaying page 1 of 11.
	
	
	| EudraCT Number: 2004-002852-33 | Sponsor Protocol Number: TOR-RIS-2004-01 | Start Date*: 2005-04-13 | |||||||||||
| Sponsor Name:Dr. Jose Vicente Torregrosa Prats (fundacio clinic) | |||||||||||||
| Full Title: a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantation Ensayo aleatorio, abierto ... | |||||||||||||
| Medical condition: bone metabolic pathology associated to kidney transplantation | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002095-10 | Sponsor Protocol Number: MV-2-2017 | Start Date*: 2017-09-13 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest | ||||||||||||||||||||||||||||||||||||||
| Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in Chronic Kidney D... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification | ||||||||||||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-004422-31 | Sponsor Protocol Number: FKS518-002 | Start Date*: 2021-02-23 | |||||||||||
| Sponsor Name:Fresenius Kabi SwissBioSim GmbH | |||||||||||||
| Full Title: A Double-blind, Randomized, Multicenter, Multiple-dose, 2-arm, Parallel-group Study to Evaluate Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 - Proposed Biosimilar to Denosumab w... | |||||||||||||
| Medical condition: Osteoporosis in Postmenopausal Women | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: HU (Completed) BG (Completed) EE (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-012189-30 | Sponsor Protocol Number: BC1-09 | Start Date*: 2009-10-30 | |||||||||||
| Sponsor Name:Algeta ASA | |||||||||||||
| Full Title: An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy | |||||||||||||
| Medical condition: Breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for further endocrine therapy | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002096-26 | Sponsor Protocol Number: MV-3-2017 | Start Date*: 2017-08-24 | ||||||||||||||||||||||||||
| Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest | ||||||||||||||||||||||||||||
| Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in dialysis patients. | ||||||||||||||||||||||||||||
| Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification | ||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2015-005585-32 | Sponsor Protocol Number: 111111733104 | Start Date*: 2016-06-24 | |||||||||||
| Sponsor Name:Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen | |||||||||||||
| Full Title: Synergy effect of the appetite hormone GLP-1 (LiragluTide) and Exercise on maintenance of weight loss and health after a low calorie diet - the S-LiTE randomized trial | |||||||||||||
| Medical condition: Obesity | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002241-18 | Sponsor Protocol Number: 983.974.742 | Start Date*: 2023-03-14 | 
| Sponsor Name:Helse Bergen HF | ||
| Full Title: Diagnostic treatment-trial for autonomous cortisol secretion- a tool to select patients for adrenalectomy | ||
| Medical condition: autonomous cortisol secretion | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-005096-27 | Sponsor Protocol Number: MBPS205 | Start Date*: 2017-06-23 | |||||||||||
| Sponsor Name:Mereo BioPharma 3 Ltd. | |||||||||||||
| Full Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusu... | |||||||||||||
| Medical condition: Osteogenesis imperfecta | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003888-56 | Sponsor Protocol Number: 20192022 | Start Date*: 2021-01-30 | |||||||||||
| Sponsor Name:Department of Nephrology, Herlev & Gentofte Hospital, Herlev Hospital | |||||||||||||
| Full Title: Treatment of adynamic bone disorder with parathyroid hormone in patients with chronic kidney disease | |||||||||||||
| Medical condition: | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-000981-46 | Sponsor Protocol Number: IC2015-13 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:INSTITUT CURIE | |||||||||||||
| Full Title: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years - | |||||||||||||
| Medical condition: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years | |||||||||||||
| 
 | |||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-002630-17 | Sponsor Protocol Number: NBK132/2/2021 | Start Date*: 2022-02-02 | 
| Sponsor Name:Medical Unicersity of Gdansk | ||
| Full Title: Treatment of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and Dexamethasone (BGD) with autologous bone marrow transplantation in lymphoma patients Hodgkin resistant to treatmen... | ||
| Medical condition: Refractory / relapsed Hodgkin's lymphoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: PL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-002274-31 | Sponsor Protocol Number: U1111-1215-8606 | Start Date*: 2020-12-16 | |||||||||||
| Sponsor Name:Department of Biomedical Sciences, University of Copenhagen | |||||||||||||
| Full Title: Young adults with early-onset obesity treated with semaglutide | |||||||||||||
| Medical condition: Obesity | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-002607-17 | Sponsor Protocol Number: TSX/01/C | Start Date*: 2005-11-18 | 
| Sponsor Name:Prostrakan Pharmaceuticals Ltd | ||
| Full Title: Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus | ||
| Medical condition: Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-000404-35 | Sponsor Protocol Number: 80519 | Start Date*: 2022-07-26 | 
| Sponsor Name:AMC, Cardiovascular Sciences | ||
| Full Title: Does the hematopoietic stem cell govern residual inflammatory cardiovascular risk in type 2 diabetes? | ||
| Medical condition: Inflammation in patients with type 2 diabetes | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-006692-20 | Sponsor Protocol Number: independant Trial (TOMIBA-TRIAL01) | Start Date*: 2007-09-06 | 
| Sponsor Name:St. Vincent Hospital, Medical Department II | ||
| Full Title: The TOMIBA study Treatment of Osteoporotic Men With Intravenous Ibandronate An open-label, single-center, prospective Phase III study | ||
| Medical condition: Osteoporosis in Men | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-002387-33 | Sponsor Protocol Number: VitalD | Start Date*: 2008-06-03 | |||||||||||
| Sponsor Name:Hôpital Erasme | |||||||||||||
| Full Title: Impact of 25-hydroxy vitamin D deficiency and its correction on mineral and bone disorde among hemodialysis patients | |||||||||||||
| Medical condition: 25-OH vitamin D deficiency and mineral - bone disorder in hemodialysis patients | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-004430-96 | Sponsor Protocol Number: 201600107 | Start Date*: 2017-12-11 | 
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk | ||
| Medical condition: Testicular cancer | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-001511-22 | Sponsor Protocol Number: 004 | Start Date*: 2005-08-24 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., | |||||||||||||
| Full Title: A 5-Year Open Label Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in the Treatment of Postmenopausal W... | |||||||||||||
| Medical condition: Postmenopausal Osteoporosis | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: SE (Completed) DK (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-002991-40 | Sponsor Protocol Number: A6281269 | Start Date*: 2015-04-01 | 
| Sponsor Name:Pfizer Inc | ||
| Full Title: Evolution of Growth Rate in Children Suffering From a Disease Associated With Growth Retardation and Treated by Genotonorm. A Pilot Study | ||
| Medical condition: Growth Disorders, Growth Retardation | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2016-003606-14 | Sponsor Protocol Number: SCH-2013 | Start Date*: 2017-01-31 | |||||||||||
| Sponsor Name:Sheffield Children's NHS Foundation Trust | |||||||||||||
| Full Title: Do bisphosphonates alter the skeletal response to mechanical stimulation in children with osteogenesis imperfecta? | |||||||||||||
| Medical condition: Osteogenesis Imperfecta | |||||||||||||
| 
 | |||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
 .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
 Query did not match any studies.
    	Query did not match any studies.
     
				
